SAN DIEGO, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., the company’s president and chief executive officer, will participate in a keynote panel at the 2017 World Antimicrobial Resistance Congress being held September 14-15 in Washington, D.C. The interactive panel will focus on a discussion of key challenges for advancing antibiotic development and incentives that can help spur innovation in the antimicrobial space.
Details of the panel are as follows:
Session Title: Igniting continuous support – how can industry keep the antibiotic pipeline afloat?
- Commitment from small, medium and large pharmaceutical companies to keep investing in the antibiotic field
- From push to pull incentives - what can industry do to keep driving the conversation and tangible outcomes?
- Striving in R&D, balancing risk-benefit assessments and overcoming regulatory setbacks. What is the key?
Date and time: Thursday, September 14, 2017 at 9:40 a.m. Eastern Time
Location: JW Marriott Hotel, Washington, D.C.
Dr. Stein is also the chairman of the Antimicrobials Working Group (AWG), an industry-led coalition of emerging antimicrobial companies that provides a collective voice in policy and regulatory solutions. He is widely recognized within the industry for his expertise in the discovery and development of antimicrobials.
Antimicrobial resistance is a growing public health threat. In the United States alone, the Centers for Disease Control and Prevention estimates that at least two million people acquire resistant infections each year and approximately 23,000 people die as result of these infections. It is also estimated that drug-resistant infections are associated with healthcare costs ranging from $20 to $25 billion in the United States.
Cidara Therapeutics is working to help combat this growing threat by developing novel anti-infectives that address the unmet need for new therapeutic approaches to treat and prevent fungal and bacterial infections - particularly those that are less susceptible to existing anti-infectives. The company has a number of studies underway investigating the full clinical utility of its novel echinocandin antifungal CD101 as well as its Cloudbreak™ immunotherapies across a range of formulations and indications.
As the leading conference on antimicrobial resistance, the World Antimicrobial Resistance Congress gathers key stakeholders from government, funding agencies, pharma, academia, hospitals, and payers to discuss change on both the scientific and economic sides of the antimicrobial resistance space. More information about the 2017 World Antimicrobial Congress can be found at: http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/index.stm
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, and other attributes of CD101 and CD201 and other potential product candidates, including the potential for these compounds to successfully treat or prevent infections, including those caused by resistant pathogens, and potentially transform the way infectious diseases are treated, and the potential for the Cloudbreak platform to result in future drug candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Robert H. Uhl
Westwicke Partners, LLC
Sam Brown Inc.
Cidara Therapeutics, Inc.